We obtained miRNA-seq data from 33 cancer types in the TCGA database (https://portal.gdc.cancer.gov/), including 521 primary lung adenocarcinoma (LUAD) tumor samples and 46 paired adjacent normal lung tissues. The raw sequencing data were processed using the BCGSC miRNA Profiling Pipeline and normalized to reads per million (RPM) mapped reads. All analyses were performed in R (version 4.2.1) without log transformation or batch correction to maintain data integrity. Corresponding clinical data were retrieved from the TCGA-LUAD dataset for integrated analysis.

A total of 45 paired tumor and adjacent normal tissue specimens were obtained from lung adenocarcinoma patients undergoing surgical resection at the Department of Thoracic Surgery, Affiliated Hospital of Chengde Medical University. All specimens were immediately snap-frozen in liquid nitrogen following surgical resection and stored at -80 °C until subsequent experiments. Among them, 27 were female and 18 were male; 28 cases were ≥ 60 years old and 17 cases were < 60 years old, with an average age of (62.29 ± 7. 45) years old; 23 cases were in stage I and 22 cases were in stage II; 3 cases were poorly differentiated, 39 cases were moderately differentiated and 3 cases were well differentiated; Lymphatic metastasis in 6 cases. Inclusion criteria: 1. Patients with lung adenocarcinoma confirmed by pathology; 2. No anti-tumor treatment (radiotherapy, chemotherapy, immunotherapy, or anti-tumor ready-for-use traditional Chinese medicine treatment) has been performed before taking the specimen; 3 Patients who have never had any other malignant tumors. Exclusion criteria: 1. Patients with incomplete data and or other malignant tumors; 2. Patients who had undergone radiotherapy and chemotherapy, and other anti-tumor treatments, before surgery. Human lung adenocarcinoma cells A549, H1299, and normal lung epithelial cells BEAS-2B were derived from the central laboratory of Affiliated Hospital of Chengde Medical University. The study was approved by the hospital ethics committee, and informed consent was obtained from patients.

Serum and basal medium were purchased from Punosai Life Technology Co., Ltd.; miR-582-3p mimics (miR-582-3p mimics) and negative control (mimics NC) were purchased from Anhui Jinbiao Biotechnology Co., Ltd.; PTPRCAP overexpression plasmid was purchased from Nanjing Jingpusaier Biotechnology Co., Ltd.; Lipofectamine 3000 transfection reagent, PTPRCAP primer and GAPDH primer were purchased from Invitrogen, USA; Dual-Lucifarase Reporter Assay System was purchased from Promega Corporation, USA; miR-582-3p primer and U6 primer were purchased from Tiangen Biochemical Technology (Beijing) Co., Ltd.; Reverse transcription kit, real-time fluorescent polymerase chain reaction (RT-qPCR) kit and CCK-8 kit were purchased from Cisco Biotechnology Co., Ltd.; Matrigel was purchased from Biozellen Corporation, USA; PTPRCAP antibody was purchased from Wuhan Sanying Biotechnology Co., Ltd., China, and GAPDH antibody was purchased from Wuhan Sevier Biotechnology Co., Ltd.; β-catenin antibody was purchased from Huaan Biotechnology Co., Ltd.; GSK3β and p-GSK3β antibodies were purchased from Ebiwei Biotechnology Co., Ltd.; Goat anti-rabbit immunoglobulin G secondary antibody was purchased from Aibotek Biotechnology Co., Ltd.

BEAS-2B, A549, and H1299 cells were resuscitated and passaged in DMEM, RPMI-1640, and F12K medium, respectively, supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin, followed by incubation in a constant-temperature incubator. A549 and H1299 cells were seeded into 6-well plates, and upon reaching approximately 80% confluence, they were transfected using Lipofectamine 3000 transfection reagent. The cells were divided into the following groups: the miR-582-3p group, miR-NC group, OE group, Vector group, miR-582-3p + OE group, and miR-582-3p + Vector group. Specifically, the miR-582-3p group and miR-NC group were transfected with miR-582-3p mimics and mimics NC at a final concentration of 100 nM, respectively; the OE group and Vector group were transfected with the PTPRCAP overexpression plasmid and the corresponding control plasmid at 2500 ng per well, respectively; and the miR-582-3p + OE group and miR-582-3p + Vector group were co-transfected with the respective reagents. After transfection, cells were initially cultured in basal medium for 24 h, followed by replacement with complete medium containing 10% FBS for an additional 24 h before subsequent experiments.

The tissues were ground with a low-temperature tissue homogenizer, and the total RNA of tissues and cells was extracted with Trizol reagent, and the RNA was reverse transcribed into cDNA by a reverse transcription kit. The configuration of the RT-qPCR system and the reaction conditions were carried out in strict accordance with the instructions of the fluorescence quantification kit. The relative quantities were calculated using the 2^-ΔΔct method. PTPRCAP forward primer sequence 5’-CAGGACACACAGACTATGACCACG-3’ ́; Reverse primer sequence 5’-GTCACTGTCTCTGGCTTCCTCA-3’. GAPDH forward primer sequence 5’-CGACCACTTTGACAAGCTCA-3’ ́, reverse primer sequence 5’-AGGGGTCTACATGGCAACTG-3’ ́. miR-582-3p forward primer sequence 5’-UCAGUGACAGUAGUUUGUCAAG-3’; Reverse primer sequence 5’-CCAGTGCAGGGTCCGAGGT-3’. U6 forward primer sequence 5’-CTCGCTTCGGCAGCACA-3’; Reverse primer sequence 5’-AACGCTTCACGAATTTGCGT-3’.

Tissue sections were dewaxed, repaired by microwave antigen retrieval, and incubated in 3% hydrogen peroxide blocking solution for 15 minutes. After the sections were cooled, 10% goat serum was blocked; Primary antibody (PTPRCAP 1: 500) was added dropwise at 4°C overnight; The next day, the primary antibody was rewarmed for 1h; Add secondary antibody dropwise and incubate at 37°C for 30 min; DBA color development, hematoxylin counterstaining, dehydration transparency, gum sealing, microscope observation results. The percentage score of positive cells was 0-4 (0 was 0%-5%, 1 was 5%-24%, 2 was 25%-49%, 3 was 50%-74%, and 4 was 75%-100%). The staining intensity score was 0 ~ 3 (0 was negative staining, 1 was weak staining, 2 was moderate staining, and 3 was strong staining). Immunoreactive Score (IRS) was calculated as IRS = PP*SI, where PP represents the score of the percentage of positive cells and SI is the level of staining intensity.IRS ≤ 2 was classified as low expression, and > 2 as high expression.

Potential interactions between miR-582-3p and PTPRCAP, along with the predicted binding sites, were identified using Target Scan. To experimentally validate this interaction, we constructed wild-type (WT-PTPRCAP) and mutant (MUT-PTPRCAP) luciferase reporter vectors containing the putative miR-582-3p binding sequence. A549 and H1299 cells were seeded in 6-well plates and co-transfected with either miR-582-3p mimics or mimics NC, along with the respective reporter vectors (WT-PTPRCAP or MUT-PTPRCAP). Following transfection, cells were cultured in basal medium for 24 h, followed by replacement with complete medium (10% FBS) for an additional 24 h. Luciferase activity was measured using a dual-luciferase reporter assay system, and the relative activity was determined by calculating the ratio of firefly luciferase to Renilla luciferase luminescence. This assay confirmed the regulatory effect of miR-582-3p on PTPRCAP expression.

Total protein was extracted from each experimental group and quantified. Protein samples were separated by SDS-PAGE (160 V constant voltage) and transferred to methanol-activated PVDF membranes (400 mA constant current). After transfer, membranes were blocked with 5% skim milk in TBST for 2h at room temperature, followed by incubation with primary antibodies: anti-PTPRCAP (1:1000), anti-GAPDH (1:4000), anti-β-catenin (1:1000), anti-GSK3β (1:2000), and anti-p-GSK3β (1:4000) at 4 °C overnight. The next day, membranes were rewarmed for 1 h, washed with TBST (3×10 min), and incubated with HRP-conjugated secondary antibody (1:10000) for 1h. After final washes (3×10 min TBST), protein bands were visualized using the C300 imaging system. Band intensities were quantified using ImageJ software by calculating the ratio of target protein to GAPDH signal.

The cell suspensions were counted and seeded into 96-well plates with 6 replicate wells in each group, and 100 μl of cell suspension containing 2500 cells was added to each well. After the cells were cultured for 0 h, 24 h, 48 h, 72 h, 10 μl of CCK-8 reagent was added to each well. After continued incubation in a 37°C incubator for 2 hours, the absorbance value (OD value) at 450 nm wavelength was measured with a microplate reader.

A549 cells and H1299 cells were seeded in 6-well plates, with 3 double wells in each group. When the cell density reaches about 80%, transfection is carried out. After the cells are cultured until the bottom of the well is covered, the bottom of the vertical well plate is scratched with the tip of a 10 μl pipette. The floating cells were washed off with PBS and added to basal medium for culture. The scratched areas were photographed under an inverted microscope at 0 h and 24 h, respectively.

Migration assay: Forty-eight hours post-transfection, cells (3×10⁴/well) in 1% FBS medium were seeded into the upper chamber, while the lower chamber contained 700 μl of 20% FBS medium. After 24 h incubation, non-migrated cells were removed by a cotton swab. Cells that migrated through the membrane were fixed with methanol, stained with 1% crystal violet, and quantified under an inverted microscope. Invasion assay: The upper chamber was pre-coated with Matrigel (Corning). Cells (5×10^4/well) were seeded as described for the migration assay, with subsequent steps performed identically.

The data were statistically analyzed and plotted using Graphpad Prism 10.0 software. The measurement data obeying the normal distribution is represented by; t-test was used for data comparison between the two groups, and One-way ANOVA or two-way ANOVA was used for data comparison between multiple groups; Wilcoxon rank sum test was used for data that did not obey the normal distribution. Count data are shown as [Example (%)] using a paired four-cell Table χ2 test. The difference was statistically significant with P < 0.05. (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.001).

We downloaded data from the TCGA database and analyzed the expression of miR-582-3p in pan-cancer. The results showed that miR-582-3p was significantly highly expressed in a variety of tumors, including lung adenocarcinoma ( Figure 1A ). Further investigation of the TCGA-LUAD dataset showed that miR-582-3p expression was significantly higher in lung adenocarcinoma tissues than in adjacent tissues (n = 521, P = 0.018, 95%CI: 0.080-0.873, Figure 1B ). This finding was further validated in vitro. qRT-PCR analysis demonstrated that miR-582-3p expression was significantly upregulated in lung adenocarcinoma cell lines A549 and H1299 compared to normal human bronchial epithelial cells BEAS-2B, showing 3-fold (n = 5, 95%CI: 1.678-2.329, P < 0.0001) and 2.6-fold (n = 5, 95%CI: 0.997-2.273, P < 0.001) increases, respectively ( Figure 1C ). Target Scan bioinformatics prediction suggested that the PTPRCAP gene contains a binding site complementary to miR-582-3p, which indicates that PTPRCAP may be the direct target gene of miR-582-3p. We performed targeted verification that in the dual luciferase reporter experiment, the experimental group cells transfected with miR-582-3p mimics and WT-PTPRCAP showed significantly reduced relative luciferase activity compared to the control group transfected with miR-NC and WT-PTPRCAP; There was no statistically significant difference in relative luciferase activity between the experimental group cells transfected with miR-582-3p mimics and MUT-PTPRCAP compared to the control group transfected with miR-NC and MUT-PTPRCAP, indicating that there was indeed targeted binding of miR-582-3p to PTPRCAP (n = 3, 95%CI:0.189-0.321, P < 0.0001, Figures 1D, E ). The relative expression levels of PTPRCAP mRNA in 18 cases of lung adenocarcinoma and adjacent tissues, as well as normal lung epithelial BEAS-2B cells and lung adenocarcinoma A549 and H1299 cells, were detected by qRT-PCR. The results demonstrated that PTPRCAP expression was significantly downregulated in tumor tissues compared with adjacent normal tissues (P = 0.001, Figure 1F ). Notably, PTPRCAP mRNA levels in A549 and H1299 cells showed 70% (n = 4, P < 0.0001) and 50% (n = 4, P < 0.001) reductions respectively relative to BEAS-2B cells( Figure 1G ). It can be seen that miR-582-3p can target and bind PTPRCAP to play a role in LUAD.

In this study, we analyzed the relationship between miR-582-3p expression and clinicopathological features using miRNA-seq data from the TCGA-LUAD (The Cancer Genome Atlas–Lung Adenocarcinoma) dataset, processed according to the BCGSC pipeline. Our results demonstrated that miR-582-3p expression was significantly correlated with T stage, N stage, pathological stage, and overall survival (OS) (Figures 2A, B, D, I and Table 1), but not with M stage, sex, age, primary tumor location, or smoking status (Figures 2C, E-H and Table 1). Specifically, miR-582-3p expression was significantly elevated in T2, T3, and T4 stage patients compared to those with T1 disease (P = 0.005, 95%CI:0.118-0.626, Figure 2A ). Similarly, N2 and N3 stage tumors exhibited markedly higher miR-582-3p levels than N0 and N1 stage cases (P = 0.006, 95%CI:0.144-0.882, Figure 2B ). Furthermore, stage III and IV patients showed significantly increased miR-582-3p expression relative to stage I and II individuals (P < 0.001, 95%CI:0.296-0.937, Figure 2D ). Deceased patients exhibited higher miR-582-3p expression than surviving patients (P < 0.001, 95%CI:0.194-0.735, Figure 2I). Notably, the high-expression group had a greater proportion of T2-T4 stage disease (36.1% vs. 30.5%, P = 0.010), higher rates of N2-N3 lymph node metastasis (9.3% vs. 5.7%, P = 0.032), and increased prevalence of stage III-IV tumors (13.0% vs. 8.0%, P = 0.006). Importantly, patients with elevated miR-582-3p expression exhibited significantly worse mortality (20.9% vs. 14.8%, P = 0.004) ( Table 1 ). Cox regression analysis ( Table 2 ), adjusted for TNM stage and other confounding factors, confirmed that high miR-582-3p expression remained an independent prognostic predictor (HR = 1.440, 95% CI: 1.018-2.037, P = 0.039). The hazard ratio was comparable to those of T2-T4 stage (HR = 1.629, P = 0.030) and stage III-IV disease (HR = 2.376, P = 0.014). Intriguingly, while the N/M stage demonstrated prognostic significance in univariate analysis, it lost statistical significance in the multivariate model. These findings suggest that miR-582-3p may influence lung adenocarcinoma progression by enhancing local invasion and lymph node metastasis ( Table 1 ). Collectively, our results not only establish miR-582-3p as a novel prognostic biomarker but also uncover its biological relevance in key tumor progression pathways, providing a rationale for developing miR-582-3p-targeted precision diagnostic and therapeutic strategies.

The expression of PTPRCAP protein in normal lung epithelial cell line BEAS-2B and lung adenocarcinoma cell lines A549 and H1299 was detected by Western blot, and the expression of PTPRCAP protein in cancer tissues and adjacent tissues of 45 patients with lung adenocarcinoma was determined by immunohistochemistry, and the relationship between the expression level of PTPRCAP protein and clinical features was analyzed. The results of Western blot demonstrated a downregulation of PTPRCAP protein expression in lung adenocarcinoma cell lines A549 and H1299 compared to normal pulmonary epithelial BEAS-2B cells, with reductions of 20% (n = 3, P = 0.015) and 30% (n = 3, P = 0.01), respectively ( Figures 3A, B ). Immunohistochemical analysis of clinical samples revealed that the positive expression rate of PTPRCAP protein in cancerous tissue (22.22%, 10/45) was significantly lower than that in adjacent non-cancerous tissue (93.33%, 42/45), and the IRS score in the cancer group was significantly lower than that in the normal group (median = 1.8 (IQR 1.2–2.0) vs. median = 3.6 (IQR 2.8-4.0); Mann-Whitney U = 101, P < 0.0001, Figures 3C, D ). There was a statistically significant difference in the positive expression rate of PTPRCAP in patients with different TNM stages and different degrees of tissue differentiation, but there was no statistically significant difference in the positive expression rate of PTPRCAP in patients with different ages, genders, and lymph node metastasis ( Table 3 ). The above results indicate that PTPRCAP may play a certain inhibitory role in the occurrence and development of lung adenocarcinoma.

The control plasmids of miR-582-3p mimics, mimics NC, and PTPRCAP were transferred into A549 cells and H1299 cells with Lipofectamine 3000 transfection reagent, respectively, and divided into the miR-582-3p group, miR-NC group, OE group, and Vector group. The transfection efficiency of each group was verified by RT-qPCR and Western blot. After transfection of the PTPRCAP overexpression plasmid and the control plasmid, the transfection efficiency was initially revealed under the fluorescence microscope (n = 4, P < 0.001, Figure 4A ). RT-qPCR results showed that in A549 and H1299 cells, miR-582-3p expression was significantly increased following transfection with miR-582-3p mimics compared to the negative control (n = 4, P < 0.01, Figure 4B ). The expression of PTPRCAP was significantly higher in the OE group than in the Vector group (n = 4, P < 0.001, Figure 4C ). This indicates that overexpression models were successfully constructed in lung adenocarcinoma cell lines A549 and H1299. After transfection with the overexpression plasmid, Western blot results showed that the protein expression of PTPRCAP in the OE group was significantly higher than that in the Vector group in the two cells (n = 3, P < 0.001, Figures 4D, E ). Collectively, these findings suggest that each group of overexpression models has been stably constructed in A549 and H1299 cell lines, which can be used for subsequent experiments.

Following transfection with miR-582-3p mimics or negative control miRNA (miR-NC), A549 and H1299 cells were allocated into miR-582-3p and miR-NC groups, respectively. A series of functional assays, including CCK-8 proliferation, wound healing, Transwell migration and invasion, and flow cytometric apoptosis analysis, were conducted to assess the oncogenic effects of miR-582-3p. The CCK-8 assay revealed a significant enhancement in proliferative capacity in the miR-582-3p group compared to the miR-NC group for both A549 and H1299 cells (n = 3, P < 0.001; Figure 5A ). Concordantly, wound healing assays demonstrated a markedly increased migratory ability in miR-582-3p-transfected cells (n = 6, P < 0.001; Figures 5B, C ). Furthermore, Transwell assays confirmed substantial promotion of both migratory and invasive capacities, as evidenced by increased numbers of migrating and invading cells in the miR-582-3p group (n = 5, P < 0.001; Figures 5D, E ). Collectively, these results demonstrate that miR-582-3p functions as an oncomiR by promoting proliferation, migration, and invasion in lung adenocarcinoma cells.

Functional phenotypic assays confirmed the significant tumor-suppressive role of PTPRCAP in lung adenocarcinoma cells. Following the establishment of stable PTPRCAP-overexpressing cell lines, functional analyses revealed that compared to the empty vector control (Vector) group, PTPRCAP overexpression markedly suppressed malignant phenotypes in both A549 and H1299 cells. Specifically, the CCK-8 proliferation assay demonstrated a significant reduction in cell viability after 72 hours, with OD values decreased by 64% and 60% in A549 and H1299 cells, respectively (n = 3; both P < 0.01; Figure 6A ). Wound healing assays showed that the 24-hour wound closure rate was reduced by 50% and 57% in the two cell lines, respectively (n = 6; both P < 0.001; Figures 6B, C ). Furthermore, Transwell assays indicated that the number of migrating cells was reduced by 34% and 37%, while the number of invading cells was decreased by 42% and 50%, respectively (n = 4; both P < 0.01; Figures 6D, E ).

To investigate the functional impact of miR-582-3p upregulation, we assessed the protein expression of PTPRCAP and key components of the Wnt/β-catenin signaling pathway, including GSK3β, p-GSK3β, and β-catenin, by Western blot analysis. Following miR-582-3p overexpression, PTPRCAP protein levels were significantly reduced in both lung adenocarcinoma cell lines, A549 and H1299. This downregulation was more pronounced in H1299 cells (80% reduction, n = 3, P < 0.001) than in A549 cells (20% reduction, n = 3, P = 0.030) ( Figures 7A–D ). Furthermore, miR-582-3p upregulation led to decreased protein expression of GSK3β, alongside increased levels of its phosphorylated form (p-GSK3β) and β-catenin in both cell lines, with the most notable change observed in β-catenin accumulation ( Figures 7E–H ). Quantitative analysis revealed that in A549 cells, GSK3β expression was reduced by 17% (n = 9, P = 0.004), while p-GSK3β and β-catenin levels were increased by 20% (n = 9, P = 0.011) and 115% (n = 9, P < 0.0001), respectively. Similarly, in H1299 cells, GSK3β expression decreased by 25% (n = 9, P = 0.002), whereas p-GSK3β and β-catenin levels increased by 23% (n = 9, P = 0.005) and 80% (n = 9, P < 0.0001), respectively. Collectively, these results suggest that miR-582-3p-mediated regulation of PTPRCAP may potentially function through the activation of the Wnt/β-catenin signaling pathway.

To investigate the regulatory role of PTPRCAP in the Wnt/β-catenin signaling pathway, we examined the protein expression levels of key pathway components—GSK3β, p-GSK3β, and β-catenin—following PTPRCAP overexpression via Western blot analysis. The results demonstrated that PTPRCAP overexpression in lung adenocarcinoma A549 and H1299 cells significantly increased GSK3β expression while decreasing both p-GSK3β and β-catenin levels ( Figures 8A, B ). Specifically, in A549 cells, GSK3β protein levels were elevated by 23% (n = 3, P = 0.001), whereas p-GSK3β and β-catenin were reduced by 22% (n = 3, P = 0.001) and 31% (n = 3, P < 0.0001), respectively. Similarly, in H1299 cells, GSK3β expression increased by 23% (n = 3, P = 0.008), while p-GSK3β and β-catenin levels decreased by 43% (n = 3, P < 0.0001) and 22% (n = 3, P = 0.011), respectively. These findings suggest that PTPRCAP may suppress the activation of the Wnt/β-catenin pathway by upregulating GSK3β expression, inhibiting its phosphorylation, and consequently promoting β-catenin degradation. This mechanism potentially represents a crucial aspect of PTPRCAP’s tumor-suppressive function.

Rescue experiments were performed to investigate whether PTPRCAP overexpression could reverse the oncogenic effects of miR-582-3p. In A549 and H1299 lung adenocarcinoma cells, co-transfection with miR-582-3p mimics and either a PTPRCAP overexpression plasmid (miR-582-3p+OE group) or an empty vector control (miR-582-3p+Vector group) was conducted. Malignant phenotypes were subsequently assessed using CCK-8 proliferation, wound healing, and transwell migration and invasion assays. Compared to the miR-582-3p+Vector group, the miR-582-3p+OE group exhibited a significant reduction in proliferative capacity in both cell lines (n = 3, P < 0.0001; Figure 9A ). Consistently, wound healing assays demonstrated markedly impaired migratory ability in the miR-582-3p+OE group, with wound closure rates reduced by 64% (A549, n = 4, P = 0.0001) and 30% (H1299, n = 4, P < 0.0001) ( Figure 9B, C ). Furthermore, Transwell assays revealed that the number of migrating cells was decreased by 38% (A549, n = 4, P < 0.0001) and 33% (H1299, n = 4, P = 0.002), while the number of invading cells was reduced by 27% (A549, n = 4, P < 0.001) and 52% (H1299, n = 4, P < 0.0001) in the miR-582-3p+OE group ( Figures 9D, E ). These rescue results suggest that the restoration of PTPRCAP expression effectively reverses the tumor-promoting phenotypes induced by miR-582-3p overexpression, supporting the conclusion that miR-582-3p likely promotes malignant progression in lung adenocarcinoma cells, at least in part, through targeted suppression of PTPRCAP.

To investigate the regulatory relationship between miR-582-3p and PTPRCAP within the Wnt/β-catenin pathway, we co-transfected A549 and H1299 cells with miR-582-3p mimics and a PTPRCAP overexpression plasmid, followed by Western blot analysis to evaluate expression changes of PTPRCAP and key Wnt/β-catenin signaling proteins. Compared to the corresponding control group, the miR-582-3p+OE group showed a significant upregulation of PTPRCAP protein expression, with approximately 3-fold and 2-fold increases in A549 (n = 3, P = 0.005) and H1299 cells (n = 3, P = 0.007), respectively ( Figures 10A, B ). Concurrently, this intervention markedly affected the Wnt/β-catenin pathway: GSK3β protein levels increased in both cell lines, while levels of p-GSK3β and β-catenin were significantly reduced ( Figures 10C, D ). Specifically, in A549 cells, GSK3β increased by 10% (n = 3, P = 0.033), p-GSK3β decreased by 60% (n = 9, P < 0.0001), and β-catenin was reduced by 40% (n = 7, P < 0.0001). In H1299 cells, GSK3β rose by 24% (n = 3, P = 0.008), p-GSK3β declined by 58% (n = 9, P < 0.0001), and β-catenin decreased by 31% (n = 9, P < 0.0001). These results provide reverse genetic evidence suggesting that miR-582-3p may modulate the activity of the Wnt/β-catenin signaling pathway by targeted suppression of PTPRCAP.